Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease

Early Phase 1

Completed

• Conditions: Fatty Liver
• Interventions: Drug: Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate

• Registration Number: NCT00949403
• Lead Sponsor: Washington University School of Medicine

Brief Summary

The purpose of this study is to evaluate how the liver receives and uses fats for energy. This will help the investigators further understand the physical and chemical processes responsible for Non-Alcoholic Fatty Liver Disease (NAFLD) in overweight females with or without NAFLD who are scheduled to undergo gastric bypass surgery.

Detailed Description

This study involves a multidisciplinary approach that will address the metabolic mechanisms responsible for Non-alcoholic Fatty Liver Disease (NAFLD) in humans. Nonalcoholic fatty liver disease (NAFLD) has become an important public health problem in many industrialized countries because of its high prevalence, potential progression to severe liver disease, and association with cardiometabolic abnormalities, including diabetes, the metabolic syndrome, dilated cardiomyopathy, and coronary heart disease. Although obesity is an important risk factor for NAFLD many obese persons have minimal or no steatosis. The mechanism responsible for the pathogenesis of steatosis is not known, but must involve one or more of the following:

1. Increased hepatic fatty acid (FA) delivery

2. Decreased hepatic FA oxidation

3. Increased de novo lipogenesis (DNL)

4. Inadequate hepatic triglyceride secretion

We hypothesize that alterations in all of these metabolic processes are involved in the pathogenesis of NAFLD. However, a comprehensive evaluation of these factors in individual cohorts of subjects has never been performed, and the ability to measure hepatic FA oxidation in vivo in human subjects has not been available.

The following Specific Aims will be evaluated in obese women with and without NAFLD, who are scheduled for bariatric surgery:

1. Determine hepatic FA uptake and oxidation by using novel PET techniques in combination with measurements of DNL using stable isotope tracers and by assessing liver tissue FA oxidative capacity by evaluating gene expression of FA oxidative enzymes and mitochondrial content.

2. Determine hepatic fatty acid delivery by using stable isotope tracers to assess the rate of free FA (FFA) release into plasma and cellular biology methods to determine the expression and protein content of the major tissue FA transporter (CD36).

3. Determine hepatic very-low-density lipoprotein TG (VLDL-TG) secretion rate by using stable isotope tracers.

4. Determine liver histology and factors involved in inflammation and fibrosis by using routine staining and immunohistochemistry.

Study Timeline

• Study First Submitted: 2009-07-28
• Study First Submitted QC: 2009-07-29
• Study First Posted: 2009-07-30
• Study Start: 2010-07
• Primary Completion: 2011-01
• Study Completion: 2011-01-19
• Results First Submitted: 2018-02-07
• Status Verified: 2020-06
• Results First Submitted QC: 2020-06-01
• Last Update Submitted: 2020-06-01
• Results First Posted: 2020-06-22
• Last Update Posted: 2020-06-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 9

Inclusion Criteria

• Obese females with a BMI of greater then or equal to 45.
• Age range between 18-45 years.
• Patients undergoing bariatric surgery at Barnes-Jewish Hospital-St.Louis,MO.

Exclusion Criteria

• Any prior history or evidence of liver disease other than Non-Alcoholic Fatty liver Disease, severe hypertriglyceridemia and diabetes mellitis.
• Consumed greater then or equal to 20 grams of alcohol per day.
• Taking medications that are known to cause hepatic steatosis & liver damage.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Obese Females (pre-bariatric surgery)	Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate	Twenty obese females (18-45 years of age, BMI \> or equal to 45) who are scheduled to undergo bariatric surgery at Barnes-Jewish Hospital will be screened for enrollment over 2 years. They will be imaged with PET/CT and radiopharmaceuticals C-11 Acetate and C-11 Palmitate will be injected.

Primary Outcome Measures

Name	Time	Method
Hepatic Fatty Acid Oxidation	3 hours	Liver fatty acid oxidation as determined by 1-11C-palmitate PET imaging.

Trial Locations

Locations (2)

Washington University; 🇺🇸 Saint Louis, Missouri, United States

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States